Originally sourced from CMOCRO INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the […]
ResearchDx will be presenting at ASCO 2022
Irvine, CA —May 02, 2022 — ResearchDx will attend and exhibit at the ASCO Annual Meeting in Chicago, Il, June 3–7. Please visit our booth #22084, or call us at 760- 473-4295 to set up a consultation at the show.
PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
Originally sourced from Business Wire NEW YORK–(BUSINESS WIRE)–Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc. (“RDx”), a CLIA-certified, CAP-accredited […]